Kailera Therapeutics, Inc.

NASDAQ:KLRA

Biotechnology

Healthcare
$11.79 +2.66%

+$0.51 today

Market cap
$1.53B
Beta
0.00
52W Low $18.50High $28.23

Volume 0.42M

Average 0.80M

KLRA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Kailera Therapeutics, Inc.NASDAQ: KLRA

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development of $101.06M in Q2 FY2026

Q2 FY2026 research & development was $101.06M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$101.06M+42.6% QoQ
Last fiscal yearDec 2025
$109.11M— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
109.11M USD
Year-over-year change
—

Research & Development vs competitors

How KLRA compares with its peers on the latest reported figures

  • KLRA's FY2025 research & development of $109.11M is the 3rd highest of the 10 companies compared; the peer median is $70.7M.
KLRA Competitors Peer median
Research & Development for KLRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VKTXViking Therapeutics, Inc.LTM Jun 2026$509.32M +227.9%+85.3%—
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$148.75M +4.1%+17.8%2088.9%
KLRAKailera Therapeutics, Inc.FY2025$109.11M ———
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$101.27M +35.7%+54.7%—
BIOABioAge Labs, Inc.LTM Mar 2026$83.27M +36.9%+34.3%807.2%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$70.7M -6.3%+29.5%—
ALTAltimmune, Inc.LTM Mar 2026$66.77M -12.8%-2.0%185483.3%
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M -55.0%-0.4%—
VTVTvTv Therapeutics Inc.LTM Mar 2026$24.01M +104.7%+13.1%65.2%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$5.77M -21.5%-38.7%—
Peer median (excluding KLRA) $70.7M+4.1%+17.8%1448.0%

Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kailera Therapeutics, Inc.

NASDAQ:KLRA

Intrinsic Alpha fair value

Locked

Current Price

$11.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.